文献速递头颈部肿瘤放疗

一项纵向研究评估人乳头瘤病毒相关口咽癌接受放化疗患者的性健康结局与优先级

A Longitudinal Study Evaluating Sexual Health Outcomes and Prioritization in Patients Undergoing Chemoradiation for Human Papillomavirus-Associated Oropharyngeal Cancer.
PubMed 文献 · Int J Radiat Oncol Biol Phys · 2023-10-20

前瞻性观察研究纳入100例接受根治性放化疗的人乳头瘤病毒相关口咽鳞癌患者,性满意度在治疗结束时和3个月时较基线临床显著下降,但12个月时恢复到接近治疗前水平;约四分之一患者在治疗前和12个月时将保留性功能列为最高优先级。

要点

  • 性满意度在放化疗结束时(-25.4)和3个月时(-12.2)显著下降,12个月时(-3.8)未达显著。
  • 13项治疗结局优先级中,保留性功能的中位排名在治疗前为10、12个月时为9。
  • 治疗前和12个月时分别有24%和26%的患者将保留性功能列为最高优先级。

核心结论

  • 尽管放化疗急性影响性满意度,但12个月后平均性满意度恢复到接近治疗前水平。
  • 约四分之一的人乳头瘤病毒相关口咽鳞癌患者将性功能视为最重要的生存期优先级。

研究设计与样本

  • 前瞻性观察研究,从3个中心招募,2020年10月至2021年11月期间入组。
  • 128例符合条件者中招募100例,12个月时98例存活患者中有89例可获取性健康测量数据。

主要发现

  • 放化疗前平均性满意度评分为51.8(标准差=26.6)。
  • 混合模型显示,治疗结束时性满意度下降-25.4(95%CI,-30.7至-20.2),3个月时下降-12.2(95%CI,-17.3至-7.0),均为临床显著下降。
  • 12个月时性满意度变化为-3.8(95%CI,-9.0至1.4),未达统计学显著。
  • 13项治疗结局优先级中,保留性功能的中位排名在治疗前为10、12个月时为9;治疗前24%、12个月时26%的患者将其列为最高优先级。
  • 同居、有性伴侣、有性生活、较高整体健康状况、较低性健康问题、较低抑郁以及将性功能列为最高优先级与12个月时较高的性满意度评分相关。

关键数值与推荐

  • 性健康测量采用22项欧洲癌症研究与治疗组织性健康问卷。
  • 治疗结局优先级采用芝加哥优先级量表。
  • 生活质量采用30项欧洲癌症研究与治疗组织核心生活质量问卷。
  • 症状负担采用MD安德森症状量表-头颈模块。
  • 情绪困扰采用患者报告结局测量信息系统-焦虑与抑郁模块。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: The primary objectives were to describe the longitudinal course of sexual health in people undergoing curative (chemo)radiation therapy ([C)RT) for human papillomavirus-associated oropharyngeal squamous cell carcinoma (HPVOPSCC) and identify factors associated with higher sexual satisfaction 12 months after (C)RT. METHODS AND MATERIALS: Eligible participants from 3 sites were recruited to a prospective observational study between October 2020 and November 2021. Measures of sexual health (22-item European Organization for Research and Treatment of Cancer Sexual Health Questionnaire), treatment outcome priorities (Chicago Priorities Scale), quality of life (30-item European Organization for Research and Treatment of Cancer Core Quality of Life Questionnaire), symptom burden (MD Anderson Symptom Inventory-Head and Neck), emotional distress (Patient-Reported Outcomes Measurement Information System - Anxiety and Depression), and facial appearance and appearance distress (FACE-Q) were administered before, at the end, and 3 and 12 months after (C)RT. RESULTS: Of 128 eligible participants, 100 were recruited; sexual health measure data were available for 89 of 98 patients alive at 12 months. Mean sexual satisfaction scores were 51.8 (SD = 26.6) before (C)RT. Mixed model results indicated a clinically significant reduction in sexual satisfaction by the end of (-25.4; 95% CI, -30.7 to -20.2) and 3 months after CRT (-12.2; -17.3 to -7.0) but not 12 months after CRT (-3.8; 95% CI, -9.0 to 1.4). Of 13 treatment outcome priorities, "keeping sexual function" had a median rank of 10 and 9 before and 12 months after (C)RT, respectively; 24% and 26% identified it as a top priority at these times. Cohabiting, having a sexual partner, being sexually active, higher global health status, lower sexual health issues, lower depression, and considering sexual function a top priority were associated with higher sexual satisfaction scores 12 months after (C)RT. CONCLUSIONS: Although affected acutely by (C)RT, average sexual satisfaction returned to near pretreatment levels after 12 months. Sexual function is considered a top survivorship priority by approximately one-quarter of patients with HPVOPSCC.

来源:Int J Radiat Oncol Biol Phys,查看原文。版权归原作者所有。

引用

  1. McDowell L, Gough K, Fua T, et al. A Longitudinal Study Evaluating Sexual Health Outcomes and Prioritization in Patients Undergoing Chemoradiation for Human Papillomavirus-Associated Oropharyngeal Cancer. Int J Radiat Oncol Biol Phys. 2023. PMID: 37865126. doi:10.1016/j.ijrobp.2023.10.006

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。